AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option
· gurufocus.com
AstraZeneca (AZN), the oncology and rare-disease drugmaker, committed $2 billion to newly issued Summit Therapeutics equity alongside a clinical collaboration,
AstraZeneca AZN, the oncology and rare-disease drugmaker, committed $2 billion to newly issued Summit Therapeutics equity alongside a clinical collaboration, wh...